Overview:
Postpartum depression (PPD) is estimated to occur in approximately 10% to 20% of mothers worldwide and is consistently observed in both high- and low-income countries. In the US, only about 20% of women receive appropriate treatment for their depression. PPD often goes unrecognized and undertreated owing to prescriber and patient concerns about safety risks associated with drug therapies used for treatment. Consequently, PPD can harm families, leading to marital discord, impaired occupational and social functioning, and reduced infant bonding.
In this CME program, a panel of experts discusses the importance of screening for PPD and the treatment options available for patients. Effective communication with patients and new therapies for treating PPD can increase the probability of a favorable outcome.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Implement screening and diagnostic criteria for PPD in women with risk factors.
- Describe the efficacy and safety of pharmacologic therapies for management of PPD.
- Summarize nonpharmacologic approaches that are used in patients with PPD.
Rubiahna L. Vaughn, MD, MPH
Lindsay Lebin, MD, BA
Bridget King, MD
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.